CO2022000575A2 - Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico - Google Patents
Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílicoInfo
- Publication number
- CO2022000575A2 CO2022000575A2 CONC2022/0000575A CO2022000575A CO2022000575A2 CO 2022000575 A2 CO2022000575 A2 CO 2022000575A2 CO 2022000575 A CO2022000575 A CO 2022000575A CO 2022000575 A2 CO2022000575 A2 CO 2022000575A2
- Authority
- CO
- Colombia
- Prior art keywords
- hydroxybenzoyl
- egf
- amino
- caprylic acid
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
La invención se refiere a composiciones farmacéuticas que comprenden un inhibidor de PCSK9, tal como un péptido de EGF(A), y una sal de ácido N-(8-(2-hidroxibenzoil)amino)caprílico. La invención se refiere además a procesos para la preparación de dichas composiciones, y a su uso en medicina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19190506 | 2019-08-07 | ||
PCT/EP2020/072227 WO2021023855A1 (en) | 2019-08-07 | 2020-08-07 | Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022000575A2 true CO2022000575A2 (es) | 2022-04-29 |
Family
ID=67551283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0000575A CO2022000575A2 (es) | 2019-08-07 | 2022-01-24 | Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220323544A1 (es) |
EP (1) | EP4009958A1 (es) |
KR (1) | KR20220046565A (es) |
CN (1) | CN114222581A (es) |
AR (1) | AR122299A1 (es) |
AU (1) | AU2020326265A1 (es) |
BR (1) | BR112022000529A2 (es) |
CA (1) | CA3144618A1 (es) |
CO (1) | CO2022000575A2 (es) |
IL (1) | IL289505A (es) |
MX (1) | MX2022000889A (es) |
PE (1) | PE20220486A1 (es) |
TW (1) | TW202120118A (es) |
WO (1) | WO2021023855A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240036563A (ko) * | 2021-07-15 | 2024-03-20 | 노보 노르디스크 에이/에스 | N-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 정제 |
WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
ATE309197T1 (de) | 1999-02-05 | 2005-11-15 | Emisphere Tech Inc | Verfahren zur herstellung alkylierter salicylamide |
WO2001092206A1 (en) | 2000-06-02 | 2001-12-06 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
MX2009002121A (es) | 2006-09-07 | 2009-05-20 | Hoffmann La Roche | Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico. |
PL2651398T3 (pl) | 2010-12-16 | 2018-05-30 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego |
CA2837658A1 (en) | 2011-06-20 | 2012-12-27 | Genentech, Inc. | Pcsk9-binding polypeptides and methods of use |
ES2965469T3 (es) * | 2012-03-22 | 2024-04-15 | Novo Nordisk As | Composiciones que comprenden un agente de suministro y preparación de estas |
ES2952874T3 (es) | 2012-03-22 | 2023-11-06 | Novo Nordisk As | Composiciones de péptidos GLP-1 y preparación de estas |
HRP20220720T1 (hr) | 2016-01-13 | 2022-09-30 | Novo Nordisk A/S | Analozi egf(a) s masnim kiselinama kao supstituentima |
EP3474875A1 (en) * | 2016-06-24 | 2019-05-01 | H. Hoffnabb-La Roche Ag | Compositions and methods for treating cardiovascular disease |
US20200165313A1 (en) | 2017-07-19 | 2020-05-28 | Novo Nordisk A/S | Egf(a) analogues, preparation, formulations and uses thereof |
-
2020
- 2020-08-07 WO PCT/EP2020/072227 patent/WO2021023855A1/en unknown
- 2020-08-07 BR BR112022000529A patent/BR112022000529A2/pt not_active Application Discontinuation
- 2020-08-07 TW TW109126752A patent/TW202120118A/zh unknown
- 2020-08-07 CN CN202080055600.1A patent/CN114222581A/zh not_active Withdrawn
- 2020-08-07 CA CA3144618A patent/CA3144618A1/en not_active Withdrawn
- 2020-08-07 KR KR1020227004059A patent/KR20220046565A/ko unknown
- 2020-08-07 AR ARP200102265A patent/AR122299A1/es unknown
- 2020-08-07 MX MX2022000889A patent/MX2022000889A/es unknown
- 2020-08-07 PE PE2022000111A patent/PE20220486A1/es unknown
- 2020-08-07 EP EP20750288.1A patent/EP4009958A1/en not_active Withdrawn
- 2020-08-07 AU AU2020326265A patent/AU2020326265A1/en not_active Withdrawn
- 2020-08-07 US US17/628,697 patent/US20220323544A1/en not_active Abandoned
-
2021
- 2021-12-29 IL IL289505A patent/IL289505A/en unknown
-
2022
- 2022-01-24 CO CONC2022/0000575A patent/CO2022000575A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2022000889A (es) | 2022-02-14 |
AU2020326265A1 (en) | 2022-02-03 |
AR122299A1 (es) | 2022-08-31 |
BR112022000529A2 (pt) | 2022-03-03 |
PE20220486A1 (es) | 2022-04-04 |
EP4009958A1 (en) | 2022-06-15 |
CN114222581A (zh) | 2022-03-22 |
WO2021023855A1 (en) | 2021-02-11 |
KR20220046565A (ko) | 2022-04-14 |
IL289505A (en) | 2022-02-01 |
TW202120118A (zh) | 2021-06-01 |
CA3144618A1 (en) | 2021-02-11 |
US20220323544A1 (en) | 2022-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020009997A2 (es) | Composiciones sólidas que comprenden un agonista de glp-1, una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante | |
CL2020002797A1 (es) | Composiciones sólidas que comprenden un agonista de glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
CO2022005904A2 (es) | Composiciones sólidas que comprenden un inhibidor de pcsk9 y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
CO2022000578A2 (es) | Composiciones sólidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
CO2022000575A2 (es) | Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
CL2018003697A1 (es) | Interferón porcino pegilado y métodos de uso del mismo. | |
SV2017005555A (es) | Composiciones de acido obeticolico y metodos de uso | |
CL2019003324A1 (es) | Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745) | |
EA201591751A1 (ru) | Трипептидные эпоксикетонные ингибиторы протеазы | |
DOP2011000264A (es) | Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia | |
CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
CL2018003319A1 (es) | Compuestos de mic-1 y usos de estos. | |
HN2003000044A (es) | Esteres hidroxamato del acido n - (4-fenil sustituido)-antranilico. | |
UY35455A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa | |
EA202091318A1 (ru) | Препарат, содержащий аденовирус группы b | |
CO2021014260A2 (es) | Formas sólidas de un inhibidor de glyt1 | |
CL2017003201A1 (es) | Variantes de il-37 | |
CL2023000491A1 (es) | Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020). | |
ES2517741B1 (es) | Composición para reducir y/o prevenir la caída del cabello y/o estimular su crecimiento | |
BR112018070626A2 (pt) | formulação farmacêutica, e, composto ou composição para uso, uso, método ou composição | |
CO2024000581A2 (es) | Comprimido que comprende una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
AR122297A1 (es) | Composiciones sólidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
CO2024000463A2 (es) | Forma polimórfica a de n-(8-(2- hidroxibenzoil)amino)caprilato de sodio | |
CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas | |
CO2024005252A2 (es) | Dendrones peptídicos y métodos de uso de los mismos |